| Miss Jessica Danielle Copeland, APRN-C | |
|
3001 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607-6307 | |
| (813) 870-4619 | |
| (813) 554-8496 |
| Full Name | Miss Jessica Danielle Copeland |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 3001 W Dr Martin Luther King Jr Blvd, Tampa, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033708367 | NPI | - | NPPES |
| 110112000 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0203X | Pediatrics - Pediatric Critical Care Medicine | APRN11001977 (Florida) | Secondary |
| 363L00000X | Nurse Practitioner | APRN11001977 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Jessica Danielle Copeland, APRN-C 3001 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607-6307 Ph: (813) 554-8527 | Miss Jessica Danielle Copeland, APRN-C 3001 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607-6307 Ph: (813) 870-4619 |
News Archive
The Human Connectome Project, a five-year endeavor to link brain connectivity to human behavior, has released a set of high-quality imaging and behavioral data to the scientific community. The project has two major goals: to collect vast amounts of data using advanced brain imaging methods on a large population of healthy adults, and to make the data freely available so that scientists worldwide can make further discoveries about brain circuitry.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
A study has revealed how cannabidiol works against tetrahydrocannabinol to prevent psychiatric side effects.
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
› Verified 8 days ago